Market Closed -
Nasdaq
21:00:00 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
9.09
USD
|
0.00%
|
|
-0.76%
|
-18.98%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
129.1
|
192.3
|
114.4
|
252.1
|
302.9
|
248.3
|
-
|
-
|
Enterprise Value (EV)
1 |
129.1
|
192.3
|
114.4
|
252.1
|
302.9
|
248.3
|
248.3
|
248.3
|
P/E ratio
|
-10.1
x
|
-9.8
x
|
-6.57
x
|
-10.7
x
|
-18.7
x
|
43.6
x
|
9.76
x
|
4.39
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
1,131
x
|
-
|
164
x
|
14.3
x
|
4.97
x
|
3.49
x
|
2.63
x
|
EV / Revenue
|
-
|
1,131
x
|
-
|
164
x
|
14.3
x
|
4.97
x
|
3.49
x
|
2.63
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-17.7
x
|
28.2
x
|
7.47
x
|
7.47
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-5.66%
|
3.54%
|
13.4%
|
13.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
19,896
|
25,810
|
26,007
|
26,261
|
26,994
|
27,317
|
-
|
-
|
Reference price
2 |
6.490
|
7.450
|
4.400
|
9.600
|
11.22
|
9.090
|
9.090
|
9.090
|
Announcement Date
|
14/02/20
|
30/03/21
|
28/02/22
|
29/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.17
|
-
|
1.535
|
21.25
|
50
|
71.15
|
94.56
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.01
|
-17.88
|
-17.22
|
-22.59
|
-12.77
|
7.772
|
28.3
|
57.77
|
Operating Margin
|
-
|
-10,520.59%
|
-
|
-1,471.6%
|
-60.09%
|
15.54%
|
39.78%
|
61.09%
|
Earnings before Tax (EBT)
1 |
-12.78
|
-18.11
|
-17.35
|
-23.71
|
-12.77
|
8.856
|
29.72
|
69.59
|
Net income
1 |
-12.78
|
-18.11
|
-17.35
|
-23.71
|
-16.04
|
5.736
|
26.21
|
56.13
|
Net margin
|
-
|
-10,652.35%
|
-
|
-1,544.89%
|
-75.5%
|
11.47%
|
36.84%
|
59.36%
|
EPS
2 |
-0.6400
|
-0.7600
|
-0.6700
|
-0.9000
|
-0.6000
|
0.2083
|
0.9317
|
2.070
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-17.14
|
8.8
|
33.25
|
33.22
|
FCF margin
|
-
|
-
|
-
|
-
|
-80.67%
|
17.6%
|
46.73%
|
35.13%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
153.41%
|
126.85%
|
59.19%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/02/20
|
30/03/21
|
28/02/22
|
29/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
1.535
|
1.677
|
3.325
|
6.515
|
9.735
|
10.21
|
11.49
|
13.22
|
15.09
|
20.53
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.173
|
-4.207
|
-3.546
|
-5.009
|
-7.899
|
-6.135
|
-5.27
|
-4.666
|
-1.017
|
-1.818
|
-0.7366
|
1.339
|
3.405
|
4.899
|
16.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-399.67%
|
-314.25%
|
-140.33%
|
-15.61%
|
-18.67%
|
-7.21%
|
11.65%
|
25.76%
|
32.47%
|
80.84%
|
Earnings before Tax (EBT)
1 |
-4.185
|
-4.427
|
-3.696
|
-5.072
|
-8.089
|
-6.857
|
-6.052
|
-5.444
|
-1.867
|
-1.818
|
-1.9
|
0.8057
|
3.716
|
5.047
|
15.7
|
Net income
1 |
-4.185
|
-4.427
|
-3.696
|
-5.072
|
-8.089
|
-6.857
|
-6.052
|
-5.444
|
-1.867
|
-2.682
|
-1.427
|
0.6574
|
2.789
|
4.405
|
14.6
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-446.71%
|
-360.88%
|
-163.73%
|
-28.66%
|
-27.55%
|
-13.97%
|
5.72%
|
21.1%
|
29.19%
|
71.1%
|
EPS
2 |
-0.1600
|
-0.1800
|
-0.1400
|
-0.1900
|
-0.3100
|
-0.2600
|
-0.2300
|
-0.2100
|
-0.0700
|
-0.1000
|
0.2133
|
0.0117
|
0.0867
|
0.1417
|
0.3400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
28/02/22
|
12/05/22
|
12/08/22
|
11/11/22
|
29/03/23
|
11/05/23
|
03/08/23
|
06/11/23
|
21/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-17.1
|
8.8
|
33.3
|
33.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/02/20
|
30/03/21
|
28/02/22
|
29/03/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
9.09
USD Average target price
18.33
USD Spread / Average Target +101.69% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.98% | 246M | | -1.65% | 104B | | +6.75% | 97.47B | | +5.71% | 22.25B | | -12.60% | 21.68B | | -9.70% | 18.2B | | -39.98% | 17.02B | | -10.17% | 16.36B | | +6.12% | 14.39B | | +35.47% | 12.37B |
Bio Therapeutic Drugs
|